CHAO YANG

Dr. CHAO YANG


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
FCFei Cai
Fei Cai
HJHuanzong Jiang
Huanzong Jiang
YLYan Li
Yan Li
QLQin Li
Qin Li
CYCHAO YANG
CHAO YANG
Diabetic retinopathy (DR) is a severe diabetes-induced eye disease, in which its pathological phenomena basically include abnormal proliferation, migration, and angiogenesis of microvascular endothelial cells in the retina. Long non-coding RNAs (lncRNAs) have been proven to be important regulators in various biological processes, but their participation in DR remains largely undiscovered. In the present study, we aimed to unveil the role of lncRNA small nucleolar RNA host gene 16 (SNHG16) in regulating the functions of human retinal microvascular endothelial cells (hRMECs) under a high-glucose (HG) condition. We found that SNHG16 expression was significantly upregulated in hRMECs treated with HG. Functionally, SNHG16 could facilitate hRMEC proliferation, migration, and angiogenesis. Moreover, SNHG16 was associated with nuclear factor κB (NF-κB) and phosphatidylinositol 3-kinase (PI3K)/AKT pathways. Mechanistically, SNHG16 could promote hRMEC dysfunction by sequestering microRNA (miR)-146a-5p and miR-7-5p to act as a competing endogenous RNA (ceRNA) with interleukin-1 receptor-associated kinase 1 (IRAK1) and insulin receptor substrate 1 (IRS1). In conclusion, our results illustrated the potential role of SNHG16 in facilitating hRMEC dysfunction under HG treatment, providing a novel approach for DR therapy.

27 December 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
BXBaikang Xie
Baikang Xie
WTWenjing Tang
Wenjing Tang
SWShuang Wen
Shuang Wen
FCFen Chen
Fen Chen
CYCHAO YANG
CHAO YANG
WLWei Liang
Wei Liang
Growth differentiation factor-15 (GDF-15) is proposed to be strongly associated with several cardiovascular diseases, such as heart failure and atherosclerosis. Moreover, some recent studies have reported an association between GDF-15 and platelet activation. In this study, we isolated peripheral blood platelets from healthy volunteers and evaluated the effect of GDF-15 on adenosine diphosphate (ADP)-induced platelet activation using the platelet aggregation assay. Subsequently, we detected the expression of GDF-15-related receptors on platelets, including the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), transforming growth factor-beta receptor I (TGF-βRI), transforming growth factor-beta receptor II (TGF-βRII), glial-cell-line-derived neurotrophic factor family receptor α-like (GFRAL), and those rearranged during transfection (RET). Then, we screened for GDF-15 receptors using the GDF-15-related receptor microarray comprising these recombinant proteins. We also performed the immunoprecipitation assay to investigate the interaction between GDF-15 and the receptors on platelets. For the further exploration of signaling pathways, we investigated the effects of GDF-15 on the extracellular signal-regulated kinase (ERK), protein kinase B (AKT), and Janus kinase 2 (JAK2) pathways. We also investigated the effects of GDF-15 on the ERK and AKT pathways and platelet aggregation in the presence or absence of RET agonists or inhibition. Our study revealed that GDF-15 can dose-independently inhibit ADP-induced human platelet aggregation and that the binding partner of GDF-15 on platelets is GFRAL. We also found that GDF-15 inhibits ADP-induced AKT and ERK activation in platelets. Meanwhile, our results revealed that the inhibitory effects of GDF-15 can be mediated by the GFRAL/RET complex. These findings reveal the novel inhibitory mechanism of ADP-induced platelet activation by GDF-15.

4 November 2020 in Chinese Medical Journal
Verified
Journal Article
Open access
CLChong Lu
Chong Lu
HWHan-Yu Wang
Han-Yu Wang
XCXiao Chen
Xiao Chen
ZWZi-Ling Wu
Zi-Ling Wu
SMShan Meng
Shan Meng
HSHui Sun
Hui Sun
An abstract is unavailable. This article is available as a PDF only.

24 May 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
WWWanying Wu
Wanying Wu
WTWenjing Tang
Wenjing Tang
WLWei Liang
Wei Liang
QLQin Li
Qin Li
XQXiaoyu Qi
Xiaoyu Qi
SWShuang Wen
Shuang Wen

11 May 2022 in JTCVS Techniques
Verified
Journal Article
Open access
HJHuanzong Jiang
Huanzong Jiang
QLQin Li
Qin Li
FCFei Cai
Fei Cai
XQXiaoyu Qi
Xiaoyu Qi
MWMincheng Wang
Mincheng Wang
CYCHAO YANG
CHAO YANG

25 October 2024 in Advanced Science
Verified
Journal Article
Open access
THTianming Huang
Tianming Huang
XQXiaoyu Qi
Xiaoyu Qi
LCLan Cao
Lan Cao
MYMing Yang
Ming Yang
HLHuan Luo
Huan Luo
CYCHAO YANG
CHAO YANG
Two indices, indicating the regional average stiffness and the pace of strain hardening respectively, are derived from the nonlinear stress–strain behavior obtained from biomechanical analysis of aneurysm. A comprehensive method based on electrocardiographic‐gated multidimensional dynamic computed tomography angiography (MD CTA) is developed for extracting these mechanical characteristics in vivo. The proposed indices are evaluated by 26 cases including 9 healthy, one aortosclerosis, and 16 abdominal aortic aneurysm cases. The difference of SSI and dSSI value between aneurysmal and healthy groups is up to orders in magnitude. Significant correlation of these indices with the clinical indicator of aneurysm diameter is found. Logistic models based on these indices are capable to sharply discriminate the healthy and the aneurysmal arteries with AUC>0.98. This work introduces new tools and new indices for aortic mechanical assessment which may shed light on understanding the mechanical condition, pathological state and eventually benefit clinical decision‐making.